A certain Ethereum ICO period whale transferred 6022 ETH to the Ethereum Foundation address 2 hours ago

October 5th - Shares of the restaurant chain Texas Roadhouse (ticker: TXRH.O) rose 1.2% in pre-market trading to $158.01 after Evercore ISI upgraded the stock from "in line" to "outperform." The brokerage lowered its target price from $220 to $200, which still represents a 28% upside from the stock's previous closing price of $156.14. Evercore stated that the comprehensive deployment of digital kitchen systems gives the restaurant greater confidence to manage peak-time demand, which will drive further growth in its takeout business and allow the company to test new menu items after years of limited innovation. The brokerage added that Texas Roadhouse’s pricing strategy is to keep prices below the inflation rate while continuing to focus on service, value, and execution, which should help maintain strong same-store sales growth. Of the 28 brokers covering the stock, 16 have a "buy" or higher rating, while 12 have a "hold" rating; the median target price is $211, according to LSEG compiled data. As of yesterday’s close, the stock is down about 6% year-to-date. (For the convenience of non-English speakers, Reuters has automated the translation of this report into several other languages. Because automated translation may be inaccurate or lack necessary context, Reuters does not guarantee the accuracy of automated translation texts and provides them solely for readers' convenience. Reuters assumes no responsibility for any harm or loss resulting from the use of the automated translation function.)

On October 5th, shares of diagnostic equipment supplier Lumexa Imaging (LMRI.O) rose 2% in pre-market trading to $10.6. Brokerage Truist Securities initiated coverage with a “Buy” rating and a target price of $18, which implies about 74% upside from the previous trading day’s close. The company offers diagnostic imaging services, including MRI, CT, and PET scans, as well as X-ray, ultrasound, and mammography services. All five brokerages currently covering LMRI have assigned it a “Buy” or higher rating, with a median target price of $17.50, according to data compiled by LSEG. As of the previous close, LMRI’s share price has declined 44.22% year-to-date. (For non-English speakers, Reuters automatically translates its reports into several languages. Due to the possibility of errors or missing context in automated translations, Reuters does not guarantee their accuracy and provides these translations solely for reader convenience. Reuters accepts no liability for any damage or loss arising from the use of automated translation.)

Reuters, October 5 – U.S. biotechnology company Alector announced on Monday that Swiss pharmaceutical giant Roche will pay up to 1.27 billion dollars to obtain licensing rights for its experimental Parkinson's disease therapy. Boosted by this news, Alector’s shares surged 72% in pre-market trading. Genentech, a subsidiary of Roche, will pay Alector a 100 million dollar upfront payment, with an additional payment of up to 1.17 billion dollars if the therapy meets certain developmental, regulatory, and sales milestones. Alector will also receive royalty payments. Specific details are as follows: the agreement grants Genentech exclusive global rights to develop, produce, and commercialize AL050, an experimental therapy targeting enzyme deficiency associated with Parkinson’s disease. Genentech will be responsible for the development, regulatory filings, production, and commercialization of the therapy. AL050 is an enzyme replacement therapy designed to address GCase enzyme deficiency—which leads to the buildup of certain fats and increases the risk of Parkinson’s. This deal is the latest in a series of licensing agreements Roche has reached to expand its drug development pipeline. In June, Roche and Nurix Therapeutics entered into a licensing and collaboration agreement involving a blood cancer medication, with a deal value of up to 2.3 billion dollars.

08:10 AM EDT, 10/05/2026 (MT Newswires) -- Harrow (HROW) said Monday that it has closed its earlier stated acquisition of Tyrvaya from Viatris (VTRS), acquiring worldwide rights to the nasal spray, except for Japan. Harrow said that, in accordance with the terms reported in August, the company paid $30 million in cash at closing and may pay up to $70 million in sales-based milestones. Tyrvaya is an FDA-approved nasal spray for dry eye disease, Harrow said. Harrow said it expects the product to generate more than $30 million in revenue next year.